Circular Tau-TfR Aptamers for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating tauopathies, such as Alzheimer's disease and traumatic brain injury, face challenges due to low specificity, difficulty in quality control, and inefficient penetration of therapeutic agents across the blood-brain barrier, limiting their effectiveness.
Innovation Solution
Development of Tau-binding DNA aptamers, specifically circular Tau-TfR bispecific aptamers, which utilize transferrin receptor-mediated transcytosis to cross the blood-brain barrier and target Tau protein, offering improved specificity, stability, and brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (mass spectrometry, PET imaging, western blotting) are used to detect Tau and P-Tau, then detection capability is achieved, but sample amount required is large and operational complexity increases
Solution Approach 1:
The patent extracts the essential detection function from complex diagnostic systems by using aptamers that directly bind to Tau and P-Tau proteins. This simplifies the diagnostic approach from multi-step procedures (mass spectrometry, western blotting) to a single-step aptamer-based detection method, reducing operational complexity while maintaining detection capability.
Solution Approach 2:
The patent introduces aptamers as intermediary molecules that mediate between the detection system and Tau/P-Tau proteins. These aptamers serve as simplified mediators that replace complex diagnostic equipment and procedures, enabling direct detection with reduced sample requirements and operational steps.
2Reliability
If therapeutic antibodies and drug candidates are administered to treat tauopathies, then treatment capability is provided, but blood-brain barrier penetration is limited
Solution Approach 1:
The patent uses aptamers as intermediary therapeutic agents that can penetrate the blood-brain barrier more effectively than traditional antibodies. These aptamers mediate the delivery of therapeutic effects to Tau proteins in the brain, overcoming the barrier obstruction problem while maintaining treatment capability.
Solution Approach 2:
The patent changes the physical and chemical parameters of the therapeutic agent by using aptamers instead of antibodies. This parameter change (from large antibody molecules to smaller aptamer molecules) enables better blood-brain barrier penetration while maintaining the ability to bind and treat Tau proteins.
3Reliability
If Tau aggregation inhibitors (e.g., methylene blue) are used to prevent Tau aggregation, then aggregation inhibition is achieved, but targeting specificity is reduced
Solution Approach 1:
The patent applies local quality by designing aptamers with specific binding regions that target particular epitopes on Tau proteins. This localized specificity ensures that aggregation inhibition is achieved at the precise target site without affecting other proteins, unlike non-specific inhibitors like methylene blue that bind to hydrophobic domains of multiple proteins.
Solution Approach 2:
The patent introduces specific aptamers as intermediary molecules that mediate between the therapeutic effect and Tau proteins with high specificity. These aptamers act as precise mediators that distinguish Tau from other proteins, achieving aggregation inhibition with correct targeting rather than through non-specific hydrophobic binding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The circular Tau-TfR bispecific aptamers effectively reduce Tau and phosphorylated Tau levels in the brain, mitigating cognitive deficits and providing a potential diagnostic and therapeutic tool for tauopathies.
Implementation Method 1
circular Tau-TfR bispecific aptamers, which utilize transferrin receptor-mediated transcytosis to cross the blood-brain barrier
Implementation Method 2
The circular Tau-TfR bisspecific aptamers effectively reduce Tau and phosphorylated Tau levels in the brain
Data Source
AI summary
The lack of blood-brain barrier (BBB) penetrating ability has hindered the delivery of many therapeutic agents for tauopathy therapeutic treatment. A circular bifunctional aptamer reported here has been able to enhance the in vivo BBB penetration for improved therapy. The circular aptamer includes one transferrin receptor (TfR) aptamer to facilitate TfR-aptamer recognition-induced transcytosis across BBB endothelial cells, and one Tau protein aptamer selected to inhibit Tau phosphorylation and other tauopathy-related pathological events in the brain. This bispecific construct exhibits strong specificity towards Tau and enhanced plasma stability in comparison to linear Tau aptamer. In vivo administration of circular Tau-TfR aptamer results in a rapid uptake into relevant brain regions after crossing the BBB, such as hippocampus and cortex. A Y-shaped trispecific aptamer including one aptamer for L1CAM, one aptamer for Tau and one aptamer for TfR reported here has enhanced BBB and neuron cell membrane permeation. Bispecific and trispecific Tau aptamer coupled to a signaling moiety (such as dodecane tetraacetic acid (DOTA) or DOTA complexed to Gd+3) for neuroimaging, and bispecific or trispecific Tau aptamer coupled to protein aggregate binding moiety (such as methylene blue) for enhanced ability to disrupt tau aggregation are also contemplated in this invention.